Evaxion Reinforces Milestone Timeline and Provides Shareholder Update


COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.

See original here:
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Related Posts